Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency.

Kung C, Hixon J, Kosinski PA, Cianchetta G, Histen G, Chen Y, Hill C, Gross S, Si Y, Johnson K, DeLaBarre B, Luo Z, Gu Z, Yao G, Tang H, Fang C, Xu Y, Lv X, Biller S, Su SM, Yang H, Popovici-Muller J, Salituro F, Silverman L, Dang L.

Blood. 2017 Sep 14;130(11):1347-1356. doi: 10.1182/blood-2016-11-753525. Epub 2017 Jul 31.

2.

Diagnostic approaches for inherited hemolytic anemia in the genetic era.

Kim Y, Park J, Kim M.

Blood Res. 2017 Jun;52(2):84-94. doi: 10.5045/br.2017.52.2.84. Epub 2017 Jun 22. Review.

3.

Recommendations regarding splenectomy in hereditary hemolytic anemias.

Iolascon A, Andolfo I, Barcellini W, Corcione F, Garçon L, De Franceschi L, Pignata C, Graziadei G, Pospisilova D, Rees DC, de Montalembert M, Rivella S, Gambale A, Russo R, Ribeiro L, Vives-Corrons J, Martinez PA, Kattamis A, Gulbis B, Cappellini MD, Roberts I, Tamary H; Working Study Group on Red Cells and Iron of the EHA.

Haematologica. 2017 Aug;102(8):1304-1313. doi: 10.3324/haematol.2016.161166. Epub 2017 May 26.

4.

PKM2, cancer metabolism, and the road ahead.

Dayton TL, Jacks T, Vander Heiden MG.

EMBO Rep. 2016 Dec;17(12):1721-1730. Epub 2016 Nov 17. Review.

5.

Emerging cellular and gene therapies for congenital anemias.

Ludwig LS, Khajuria RK, Sankaran VG.

Am J Med Genet C Semin Med Genet. 2016 Dec;172(4):332-348. doi: 10.1002/ajmg.c.31529. Epub 2016 Oct 28. Review.

6.

Anti-sarcopenic effects of diamino-diphenyl sulfone observed in elderly female leprosy survivors: a cross-sectional study.

Lee SY, Kim W, Park HW, Park SC, Kim IK, Chung SG.

J Cachexia Sarcopenia Muscle. 2016 Jun;7(3):322-9. doi: 10.1002/jcsm.12074. Epub 2015 Oct 15.

7.

Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency.

Garcia-Gomez M, Calabria A, Garcia-Bravo M, Benedicenti F, Kosinski P, López-Manzaneda S, Hill C, Del Mar Mañu-Pereira M, Martín MA, Orman I, Vives-Corrons JL, Kung C, Schambach A, Jin S, Bueren JA, Montini E, Navarro S, Segovia JC.

Mol Ther. 2016 Aug;24(7):1187-98. doi: 10.1038/mt.2016.87. Epub 2016 May 3.

8.

Insight into GATA1 transcriptional activity through interrogation of cis elements disrupted in human erythroid disorders.

Wakabayashi A, Ulirsch JC, Ludwig LS, Fiorini C, Yasuda M, Choudhuri A, McDonel P, Zon LI, Sankaran VG.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4434-9. doi: 10.1073/pnas.1521754113. Epub 2016 Apr 4.

9.

Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia.

Barcellini W, Fattizzo B.

Dis Markers. 2015;2015:635670. doi: 10.1155/2015/635670. Epub 2015 Dec 27. Review.

10.

Modulation of Malaria Phenotypes by Pyruvate Kinase (PKLR) Variants in a Thai Population.

van Bruggen R, Gualtieri C, Iliescu A, Louicharoen Cheepsunthorn C, Mungkalasut P, Trape JF, Modiano D, Sirima BS, Singhasivanon P, Lathrop M, Sakuntabhai A, Bureau JF, Gros P.

PLoS One. 2015 Dec 14;10(12):e0144555. doi: 10.1371/journal.pone.0144555. eCollection 2015.

11.

Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells.

Garate Z, Quintana-Bustamante O, Crane AM, Olivier E, Poirot L, Galetto R, Kosinski P, Hill C, Kung C, Agirre X, Orman I, Cerrato L, Alberquilla O, Rodriguez-Fornes F, Fusaki N, Garcia-Sanchez F, Maia TM, Ribeiro ML, Sevilla J, Prosper F, Jin S, Mountford J, Guenechea G, Gouble A, Bueren JA, Davis BR, Segovia JC.

Stem Cell Reports. 2015 Dec 8;5(6):1053-1066. doi: 10.1016/j.stemcr.2015.10.002. Epub 2015 Nov 5.

12.

Erythrocyte pyruvate kinase deficiency: 2015 status report.

Grace RF, Zanella A, Neufeld EJ, Morton DH, Eber S, Yaish H, Glader B.

Am J Hematol. 2015 Sep;90(9):825-30. doi: 10.1002/ajh.24088. Epub 2015 Aug 14. Review.

13.

Structures of pyruvate kinases display evolutionarily divergent allosteric strategies.

Morgan HP, Zhong W, McNae IW, Michels PA, Fothergill-Gilmore LA, Walkinshaw MD.

R Soc Open Sci. 2014 Sep 24;1(1):140120. doi: 10.1098/rsos.140120. eCollection 2014 Sep.

14.

Red blood cell vesiculation in hereditary hemolytic anemia.

Alaarg A, Schiffelers RM, van Solinge WW, van Wijk R.

Front Physiol. 2013 Dec 13;4:365. doi: 10.3389/fphys.2013.00365. Review.

15.

Regulation of pyruvate metabolism and human disease.

Gray LR, Tompkins SC, Taylor EB.

Cell Mol Life Sci. 2014 Jul;71(14):2577-604. doi: 10.1007/s00018-013-1539-2. Epub 2013 Dec 21. Review.

16.

Erythrocyte pyruvate kinase deficiency mutation identified in multiple breeds of domestic cats.

Grahn RA, Grahn JC, Penedo MC, Helps CR, Lyons LA.

BMC Vet Res. 2012 Oct 30;8:207. doi: 10.1186/1746-6148-8-207.

17.

A new family of covalent inhibitors block nucleotide binding to the active site of pyruvate kinase.

Morgan HP, Walsh MJ, Blackburn EA, Wear MA, Boxer MB, Shen M, Veith H, McNae IW, Nowicki MW, Michels PA, Auld DS, Fothergill-Gilmore LA, Walkinshaw MD.

Biochem J. 2012 Nov 15;448(1):67-72. doi: 10.1042/BJ20121014.

18.

Erythrocytic pyruvate kinase mutations causing hemolytic anemia, osteosclerosis, and seconday hemochromatosis in dogs.

Gultekin GI, Raj K, Foureman P, Lehman S, Manhart K, Abdulmalik O, Giger U.

J Vet Intern Med. 2012 Jul-Aug;26(4):935-44.

19.

The crystal structure of Toxoplasma gondii pyruvate kinase 1.

Bakszt R, Wernimont A, Allali-Hassani A, Mok MW, Hills T, Hui R, Pizarro JC.

PLoS One. 2010 Sep 14;5(9):e12736. doi: 10.1371/journal.pone.0012736.

20.

Supplemental Content

Support Center